{"name":"Geropharm","slug":"geropharm","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"neuroscience","drugs":[{"name":"Insulin Humulin® NPH","genericName":"Insulin Humulin® NPH","slug":"insulin-humulin-nph","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Lispro Biphasic 25","genericName":"Insulin Lispro Biphasic 25","slug":"insulin-lispro-biphasic-25","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Rinsulin® NPH","genericName":"Insulin Rinsulin® NPH","slug":"insulin-rinsulin-nph","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"NovoRapid® Penfill®","genericName":"NovoRapid® Penfill®","slug":"novorapid-penfill","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"RinGlar®","genericName":"RinGlar®","slug":"ringlar","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"GP40081","genericName":"GP40081","slug":"gp40081","indication":"Treatment-resistant depression","status":"phase_3"},{"name":"GP40321","genericName":"GP40321","slug":"gp40321","indication":"Treatment-resistant depression","status":"phase_3"},{"name":"GP404141","genericName":"GP404141","slug":"gp404141","indication":"Multiple sclerosis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Apidra® SoloStar®","genericName":"Apidra® SoloStar®","slug":"apidra-solostar","indication":"Other","status":"marketed"},{"name":"GP40221","genericName":"GP40221","slug":"gp40221","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"GP40071","genericName":"GP40071","slug":"gp40071","indication":"Hypertension","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Prezista®","genericName":"Prezista®","slug":"prezista","indication":"HIV-1 infection in treatment-experienced patients","status":"marketed"}]}],"pipeline":[{"name":"GP40081","genericName":"GP40081","slug":"gp40081","phase":"phase_3","mechanism":"GP40081 is a small molecule drug that targets the sigma-1 receptor.","indications":["Treatment-resistant depression"],"catalyst":""},{"name":"Apidra® SoloStar®","genericName":"Apidra® SoloStar®","slug":"apidra-solostar","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GP40071","genericName":"GP40071","slug":"gp40071","phase":"phase_3","mechanism":"GP40071 is a small molecule drug that targets the renin-angiotensin system.","indications":["Hypertension","Heart failure"],"catalyst":""},{"name":"GP40221","genericName":"GP40221","slug":"gp40221","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GP40321","genericName":"GP40321","slug":"gp40321","phase":"phase_3","mechanism":"GP40321 is a small molecule that targets the serotonin receptor.","indications":["Treatment-resistant depression"],"catalyst":""},{"name":"GP404141","genericName":"GP404141","slug":"gp404141","phase":"phase_3","mechanism":"GP404141 is a small molecule drug that targets the S1P receptor.","indications":["Multiple sclerosis"],"catalyst":""},{"name":"Insulin Humulin® NPH","genericName":"Insulin Humulin® NPH","slug":"insulin-humulin-nph","phase":"phase_3","mechanism":"Insulin Humulin NPH is a human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Biphasic 25","genericName":"Insulin Lispro Biphasic 25","slug":"insulin-lispro-biphasic-25","phase":"phase_3","mechanism":"Insulin Lispro Biphasic 25 is a premixed insulin formulation that rapidly lowers blood glucose by facilitating cellular glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Rinsulin® NPH","genericName":"Insulin Rinsulin® NPH","slug":"insulin-rinsulin-nph","phase":"phase_3","mechanism":"Insulin NPH is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"NovoRapid® Penfill®","genericName":"NovoRapid® Penfill®","slug":"novorapid-penfill","phase":"phase_3","mechanism":"NovoRapid is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Prezista®","genericName":"Prezista®","slug":"prezista","phase":"marketed","mechanism":"Prezista (darunavir) is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and inhibiting viral replication.","indications":["HIV-1 infection in treatment-experienced patients","HIV-1 infection in treatment-naïve patients (in combination with other antiretrovirals)"],"catalyst":""},{"name":"RinGlar®","genericName":"RinGlar®","slug":"ringlar","phase":"phase_3","mechanism":"RinGlar is a glucagon-like peptide-1 (GLP-1) receptor agonist.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQSjQ4Y1lfS1JMbHV6b3h4aVNlRFVMeEg5aDJwbXB1MEpFZjdncmhGMThSU0dPcTd5amVjWWdWWUlCdncwaV83YmlOOUF3MmVweHRUbC15YnBIM28xVGp0UG5ueGo3NjEzblZ2QjZKLXVlSHg3ZmpzUWZGUUcyeHZwZWdZOWVHSG82bGRZRnY1ZE5XaHp5RlpEeDR6bjk1R3JROEN2cFZTbnVKVUZfVi03Qw?oc=5","date":"2026-01-14","type":"patent","source":"The Pharma Letter","summary":"Novo Nordisk trying to stop exports of Russian generic of Ozempic - The Pharma Letter","headline":"Novo Nordisk trying to stop exports of Russian generic of Ozempic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPRTRXSFpiR1dtcHA3bjQtMldZZUpiQ1pvWTRTMEluNG9nUUhraElUNE1Bcm8xU3NZTnBNdmo0cEJNaGJkMmU4S2lLeXBhSWZRaVRlbUlYamZCVW5VRlhsQ0FLNkRhUll4dWgwbklzdnRYejJaR1V6bmd3SUl4LTNOZW9CUk95cXdlTF83U2JTTi1nYU1ZLWxYcHdhcFF3YjVNX1lGcXlvVm0yYm1zbGc?oc=5","date":"2025-05-28","type":"deal","source":"The Pharma Letter","summary":"Geropharm receives compulsory license for Novo Nordisk’s Ozempic - The Pharma Letter","headline":"Geropharm receives compulsory license for Novo Nordisk’s Ozempic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOMkktSERuaUZPSm82X1JQRkZjeDNxNHNfUjNoRDVweEpqQzFIc1JqOWUtT1k1SEVvVDdZcGc3X0h6bS05X2VfYlQzX2trd09LeU1sUnJjWG1TeFRkRXcteC12NjhjZ0RBWVJVX1dtVFRReExmOXZZUE1tMWFaN0FDSFlpcHlJelB4Zi1FVmZ4MHFMRDR4b3hCaU9FMVVNUmN5c09kczVsa3c1VHFvcVFJS0c4eXVjaG1xamFsNTVB?oc=5","date":"2025-05-26","type":"pipeline","source":"Baku.ws","summary":"The Azerbaijani pharmaceutical plant \"R-PHARM\" has signed an agreement with the Russian company Gerof - Baku.ws","headline":"The Azerbaijani pharmaceutical plant \"R-PHARM\" has signed an agreement with the Russian company Gerof","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNTVNYcXdkb0x1Wkk1UWNDd1BaNkdwcnNlUGowUXV1S1VfNnNWWjNPOFZJRjJ3N1F3LVJrNTBERDVvMXdsR3g0bVFnSXFiRXA0ZkEwSXpIdU1kcEVfVTI1dEZQUUlwOFpJY2ptb1dfbkV5dk5Ec3UyR19lLUw2OEg1VnFlYUxxOVdXYWZHaC01OXhuNmo3QnBPRG9VMTdxbFkyLVpsRlQxWXN6LUnSAasBQVVfeXFMTU1TWHF3ZG9MdVpJNVFjQ3dQWjZHcHJzZVBqMFF1dUtVXzZzVlozTzhWSUYydzdRdy1SazUwREQ1bzF3bEd4NG1RZ0lxYkVwNGZBMEl6SHVNZHBFX1UyNXRGUFFJcDhaSWNqbW9XX25FeXZORHN1MkdfZS1MNjhINVZxZWFMcTlXV2FmR2gtNTl4bjZqN0JwT0RvVTE3cWxZMi1abEZUMVlzei1J?oc=5","date":"2025-04-09","type":"regulatory","source":"Новости GxP","summary":"The Ministry of Health has registered Russia’s seventh drug with semaglutide - Новости GxP","headline":"The Ministry of Health has registered Russia’s seventh drug with semaglutide - Новости GxP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdjBlRS1WNlBTamc4RzNFY1lxcUJraG5BNllYY3FOSnFLdXJKZE5nZG9TU2xtZVNDdnd1QllJaHF6Zm1vMjllbFM1WkFHejlzaGlCUkhzaTdPX2dRejA2WDlydE9zZTlRUHVPUk1GbF9JVW5jQ20wUFVpNjFhemxDTWVEeXA2R0RDLUxOa2xMVThsM3dHT0xFcEZ5cHBuclhEd2ZXdm1Hel9DUdIBqgFBVV95cUxNdjBlRS1WNlBTamc4RzNFY1lxcUJraG5BNllYY3FOSnFLdXJKZE5nZG9TU2xtZVNDdnd1QllJaHF6Zm1vMjllbFM1WkFHejlzaGlCUkhzaTdPX2dRejA2WDlydE9zZTlRUHVPUk1GbF9JVW5jQ20wUFVpNjFhemxDTWVEeXA2R0RDLUxOa2xMVThsM3dHT0xFcEZ5cHBuclhEd2ZXdm1Hel9DUQ?oc=5","date":"2024-08-12","type":"pipeline","source":"Новости GxP","summary":"Geropharm to start production of insulin glargine and aspart in Azerbaijan - Новости GxP","headline":"Geropharm to start production of insulin glargine and aspart in Azerbaijan - Новости GxP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOY3JsSU1CRkdPbzRnWWpKYjhnZmRHVGxET2tiZWdKYlJBanRXdEVOX1JPd09OcUVMUWJTclYyTllDWkJCczdQZ0hoTGQydXd1cGkzdUpIbWpLSjRxY1dLSkpUV3N0dk80Ti1EUjFGNWJrYnVLX1lhMERlWlZBQThLM2l6a29xU1AyNHJBWE1uUFM1OWRqUWtTc3FR?oc=5","date":"2024-07-12","type":"regulatory","source":"The Pharma Letter","summary":"Russian drugmaker Geropharm demands Ozempic compulsory license - The Pharma Letter","headline":"Russian drugmaker Geropharm demands Ozempic compulsory license","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdC1IU3V1TXljd292WGd0ZmFpUXdEcHJXUXhCcHFGZE1kTlZMZjQ2VnB4c3VmYXI0Rkp4RVVjVTBBODJRTkhTRW5WM2x2OWxjaGU5MnoyUEdzSDR2Z2VUSXlCV25SS2I5bkhCZ2UxRzJOYzZCUnlnZkI1ck9NblE2Njl1d2lwb25TMzd1YUpnX0NPSDlYZGR2WTliM3JXTDhhQXdid2k2b29weURSTGk5Q0RCUkdmRXNC?oc=5","date":"2024-04-09","type":"patent","source":"The Pharma Letter","summary":"Russia’s Geropharm plans to launch generic of Wegovy for treatment of obesity - The Pharma Letter","headline":"Russia’s Geropharm plans to launch generic of Wegovy for treatment of obesity","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2021-04-01","type":"pipeline","source":"Новости GxP","summary":"Russian pharmaceutical company “Geropharm” will start to produce insulin in Venezuela - Новости GxP","headline":"Russian pharmaceutical company “Geropharm” will start to produce insulin in Venezuela - Новости GxP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPMkJqTHpuUV84VWFhWUlKRUc3ekxMRVBBSVJRUjVxblpnSk5waGJGLVNuSFBfRDdsbEFLQmozWXBlYWk1OVdmM0VRRU1fMzJIdkliT3VuYXBlbU5IblplRHR5UTIwalJGOWUweXVzLXlpSXNBMVhVYnZEOGFSeHo1T3Z4dFF0TmF0ZHV3MjFsbHlYcVBFUkpQSHlHX25tQzR6cm1QNUhOQWl2SlhGQjNsOEl2QW5zYUV5alpOVzhkTQ?oc=5","date":"2019-06-11","type":"pipeline","source":"The Pharma Letter","summary":"Russia's Geropharm aims to become leading supplier of insulin in Latin America - The Pharma Letter","headline":"Russia's Geropharm aims to become leading supplier of insulin in Latin America","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_3":9,"marketed":2,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}